A randomized, placebo-controlled Phase 1b study evaluates the effects of sevuparin on the symptoms of healthy volunteer participants who have been injected with the bacterial toxin lipopolysaccharide (LPS)
Latest Information Update: 10 Oct 2023
At a glance
- Drugs Heparin (Primary) ; Sevuparin (Primary)
- Indications Endotoxinaemia; Sepsis; Septic shock
- Focus Adverse reactions; Therapeutic Use
- Acronyms lipopolysaccharide (LPS) provocation study
- Sponsors Modus Therapeutics
- 05 Oct 2023 According to a Modus Therapeutics media release, final results from this study will be presented as part of the "Best poster presentation" session at the 27th International Symposium on infections in the Critically Ill Patient (ISICIP), October 5-6 in Barcelona, Spain.
- 21 Feb 2023 Topline data results presented in a Modus Therapeutics media release.
- 21 Feb 2023 According to a Modus Therapeutics media release, company announced positive top-line data from this trial will be used to design the Modus Phase 2a study of sevuparin in patients with sepsis.